Medical News Observer

Key Points:

• EyeArt utilizes artificial intelligence to analyze retinal images for signs of diabetic retinopathy, which is compatible with specific Canon and Topcon camera models.
• It features a user-friendly interface with a Client, Server, and Analysis Computation Engine. It requires an internet connection and provides live feedback on image quality.
• Clinical studies have demonstrated high sensitivity and specificity, though accuracy depends on image quality and camera compatibility. Initial validation focused on patients not previously diagnosed with diabetic retinopathy.

Overview

EyeArt v2.2.0 is a retinal diagnostic software developed by Eyenuk Inc. This device, classified under 21 CFR 886.1100 as a Class II medical device, uses artificial intelligence to automatically detect signs of diabetic retinopathy in adult diabetic patients, aiming to improve early detection and treatment outcomes.

Indications

EyeArt is designed for healthcare providers to detect more than mild diabetic retinopathy and vision-threatening diabetic retinopathy conditions in diabetic patients not previously diagnosed with retinopathy. It’s compatible with specific models of Canon and Topcon retinal cameras.

Usage Instructions

The software integrates a Client, Server, and Analysis Computation Engine, operating through a user-friendly interface. It requires high-resolution retinal images to analyze for diabetic retinopathy, provides live feedback on image quality, and requires an internet connection for functionality.

 

Limitations

While EyeArt significantly advances diabetic retinopathy screening, its accuracy depends on image quality and specific camera compatibility. Additionally, the device’s performance is based on data from patients not previously diagnosed with diabetic retinopathy, potentially limiting its applicability to broader populations.

Study and Results

Clinical studies demonstrated EyeArt’s efficacy, including a prospective multi-center study and a retrospective analysis. These studies highlighted the software’s high sensitivity and specificity in detecting diabetic retinopathy, underscoring its potential in clinical settings.

Implications

EyeArt v2.2.0 represents a significant step forward in detecting and managing diabetic retinopathy. It offers substantial equivalence to its predicate device with added improvements. Its integration into healthcare practices can potentially enhance early detection rates, improving patient outcomes in diabetic eye care.

Reference

FDA. n.d. “K223357, EyeArt v2.2.0 510(k) Premarket Notification.” Accessed February 16, 2024. https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpmn/pmn.cfm?ID=K223357